Orrick’s Joshua Rosenkranz helped Gilead Sciences successfully defend a Federal Circuit judgment of patent invalidity. (Courtesy photo)
An all-star team of patent litigators could not persuade the U.S. Supreme Court to revive a $1.2 billion judgment over a cancer treatment patent.
The justices denied cert in Juno Therapeutics v. Kite Pharma, leaving in place a decision of the U.S. Court of Appeals for the Federal Circuit that invalidated Juno’s and Sloan Kettering Institute for Cancer Research’s 7,446,190 patent.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
